NCT00062647View on ClinicalTrials.gov

Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

August 31, 2006

Study Completion Date

August 31, 2006

Conditions
Gram-Positive Bacterial Infections
Interventions
DRUG

Telavancin

Telavancin 10mg/kg/day IV every 24 hrs for up to 14 days

DRUG

Vancomycin, nafcillin, oxacillin, or cloxacillin

Vancomycin 1 Gram every 12 hr IV (intravenously) OR nafcillin, oxacillin, or cloxacillin 2 Grams every 6 hr IV (intravenously) for up to 14 days.

Trial Locations (1)

30060

Wellstar Infectious Disease, Marietta

Sponsors
All Listed Sponsors
lead

Cumberland Pharmaceuticals

INDUSTRY